Clinical trial
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable…
NCT00227513 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00227513 |
|---|---|
| Title | Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors |
| Official title | A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Bortezomib in Patients With Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | bortezomib, vorinostat |
| Enrollment | 66 |
| Start date | Jul 1, 2005 |
| Primary completion | Jun 1, 2010 |
| First posted | Sep 28, 2005 |
| Last update posted | Feb 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: